PReS-FINAL-2172: Efficacy of corticosteroids and intravenous cyclophosphamide for patients with juvenile systemic sclerosis by M Kikuchi et al.
POSTER PRESENTATION Open Access
PReS-FINAL-2172: Efficacy of corticosteroids and
intravenous cyclophosphamide for patients with
juvenile systemic sclerosis
M Kikuchi*, T Nozawa, T Kanetaka, K Nishimura, R Hara, K Yamazaki, T Sato, N Sakurai, S Yokota
From 20th Pediatric Rheumatology European Society (PReS) Congress
Ljubljana, Slovenia. 25-29 September 2013
Introduction
Systemic sclerosis (ssc) is a rare multisystemic disease
characterized by inflammation, vascular abnormalities,
and fibrosis that affects the skin and various internal
organs. Juvenile ssc accounts for fewer than 10% of all
adults with ssc. Regarding effective treatment there were
no specific pediatric data available, and the long-term
efficacy of treatment for children with ssc has not been
investigated.
Objectives
To evaluate efficacy of treatment in juvenile ssc and to
extract factors related to poor prognosis.
Methods
Ten patients (4 boys and 6 girls) with ssc were included.
All of them were diagnosed as a diffuse type ssc based
on clinical manifestations (Raynaud’s phenomenon, skin
induration and/or internal organ involvements), serolo-
gical findings, and imaging assessments of internal
organ damages. The responses to treatment during their
clinical courses were assessed by Total Skin Score (TSS)
and internal organ damages using imaging assessment
modalities.
Results
Average onset age was 10.3 years and average duration
until diagnosis was 22 months (range 2-74 months).
Average observation period was 41 months. Nine out of
10 patients had antinuclear antibodies, and anti-Scl-70
antibody was positive in 4. Nine patients were revealed
upper gastrointestinal dysfunction, 2 were shown
interstitial lung disease, the other 2 were detected pul-
monary hypertension, and 1 had arrhythmia. All of the
patients were treated primarily with corticosteroids, fol-
lowed by intravenous cyclophosphamide (IVCY) (12
months course) as induction therapy. Most of the
patients received oral prednisolone and other immuno-
suppressants such as azathioprine, methotrexate, and
mycophenolate mofetil as maintenance therapy. Six out
of 10 patients were shown improvement of TSS, and 2
patients with pulmonary hypertension had remarkable
improvement after 2-year IVCY therapy. In 4 out of
these 6 patients both TSS and internal organ damages
were improved, and the other 2 patients ameliorated in
TSS but not in internal organ damages. TSS of 3
patients with the positive anti-Scl-70 antibody was
unchanged or increased suggesting anti-Scl-70 antibody
may be one of poor prognostic factors. Other 2 patients
with the positive anti-Scl-70 antibody were complicated
with interstitial lung disease, and they were refractory to
the treatment suggesting again the anti-Scl 70 antibody
may be one of the poor prognostic factors. Additionally,
these 2 patients received incomplete IVCY therapy due
to anaphylactic reaction to IVCY or patient’s refusal.
One female with the positive anti-Scl-70 antibody died
due to acute heart failure with no appropriate therapy in
a regional hospital, and then after being transferred to
our hospital methylprednisolone pulses and IVCY was
successfully administered for TSS improvement during 3
months, but lung fibrosis and arrhythmia were progressed.
Conclusion
The earlier diagnosis and induction of corticosteroids
and IVCY therapies will be indispensable for the preven-
tion of fatal organ involvement in juvenile ssc. Incom-
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